Androgen Deprivation Therapy

“My Prostate Test” (ArteraAI) provides individualized outcome predictions for prostatectomy, active surveillance, and the efficacy of adjuvant hormone suppression supplementing primary radiation therapy to guide management decisions.

Scott B. Sellinger, MD, FACS, addresses doublet and triplet therapies for metastatic castration-sensitive prostate cancer.

Andrew W. Hahn, MD, addresses cardiometabolic health in men with advanced prostate cancer.

E. David Crawford, MD; Scott B. Sellinger, MD; & David S. Morris, MD, FACS, discuss ADT as a foundational therapy for PCa.

E. David Crawford, MD; Neal D. Shore, MD, FACS; & Benjamin H. Lowentritt, MD, FACS, discuss ADT as a foundational therapy for PCa.

These lectures were presented during the Perspectives in Urology Point-Counterpoint Virtual Conference on November 11, 2020.

E. David Crawford, MD, Scott B. Sellinger, MD, and Paul R. Sieber, MD, discuss reinforcing consistent testosterone suppression in ADT and the role of triptorelin.